Expert Opinion on Drug Safety, Volume 21, Issue 10 (2022)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Drug Safety, Volume 21, Issue 10 (2022)

See all volumes and issues
Vol 23, 2024 Vol 22, 2023 Volume 21, 2022 Vol 20, 2021 Vol 19, 2020 Vol 18, 2019 Vol 17, 2018 Vol 16, 2017 Vol 15, 2016 Vol 14, 2015 Vol 13, 2014 Vol 12, 2013 Vol 11, 2012 Vol 10, 2011 Vol 9, 2010 Vol 8, 2009 Vol 7, 2008 Vol 6, 2007 Vol 5, 2006 Vol 4, 2005 Vol 3, 2004 Vol 2, 2003 Vol 1, 2002
Download citations Download PDFs Download issue

Editorial

Editorial
Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning
Daniel Arku, Consuela Yousef & Ivo Abraham
Pages: 1235-1238
Published online: 04 Oct 2022
AbstractforChanging paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning | Full Text | References | PDF (160.3 KB) | EPUB
  • 1658 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Drug Safety Evaluation

Article
Safety evaluation of perampanel as monotherapy or first adjunctive therapy in patients with epilepsy
James Wheless & Nitish Chourasia
Pages: 1239-1247
Published online: 30 Oct 2022
AbstractforSafety evaluation of perampanel as monotherapy or first adjunctive therapy in patients with epilepsy | Full Text | References | PDF (329.1 KB) | EPUB
  • 1850 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Article
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge
Angelo Ruggiero, Matteo Megna, Gabriella Fabbrocini, Luigi Fornaro & Alessia Villani
Pages: 1249-1257
Published online: 31 Oct 2022
AbstractforDrug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge | Full Text | References | PDF (277 KB) | EPUB
  • 311 Views
  • 3 CrossRef citations
  • 0Altmetric
Article
Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and tolerability
Francesco Oddone
Pages: 1259-1268
Published online: 26 Oct 2022
AbstractforReviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and tolerability | Full Text | References | PDF (354.9 KB) | EPUB
  • 1124 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

Special Report

Article
How do safety warnings on medicines affect prescribing?
Barbara Mintzes, Ellen Reynolds, Priya Bahri, Lucy T Perry, Alice L Bhasale, Richard L Morrow & Colin R Dormuth
Pages: 1269-1273
Published online: 19 Oct 2022
AbstractforHow do safety warnings on medicines affect prescribing? | Full Text | References | PDF (495.8 KB) | EPUB
  • 266 Views
  • 0 CrossRef citations
  • 0Altmetric

Review

Review
Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Jiahui Pan, Yuwei Liu, Xiaozhong Guo, Zhaohui Bai, Giovanni Battista Levi Sandri, Nahum Méndez-Sánchez & Xingshun Qi
Pages: 1275-1287
Published online: 16 Oct 2022
AbstractforRisk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis | Full Text | References | PDF (3.4 MB) | EPUB | Supplemental
  • 230 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
Risks and benefits of current and novel drugs to treat agitation in Alzheimer’s disease
Nathan Herrmann, Hui Jue Wang, Bing Xin Song, Kritleen K. Bawa & Krista L. Lanctôt
Pages: 1289-1301
Published online: 20 Oct 2022
AbstractforRisks and benefits of current and novel drugs to treat agitation in Alzheimer’s disease | Full Text | References | PDF (325.1 KB) | EPUB
  • 516 Views
  • 1 CrossRef citations
  • 0Altmetric

Original Research

Article
Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study
Daisuke Yabe, Fumiko Yamamoto, Søren S. Lund, Tomoo Okamura & Takashi Kadowaki
Pages: 1303-1313
Published online: 03 May 2022
AbstractforLong-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study | Full Text | References | PDF (884.3 KB) | EPUB | Supplemental
  • 2164 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Article
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Hristo Lliev & Atsutaka Yasui
Pages: 1315-1328
Published online: 30 Mar 2022
AbstractforSafety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study | Full Text | References | PDF (4.7 MB) | EPUB | Supplemental
  • 5541 Views
  • 5 CrossRef citations
  • 0Altmetric
Open Access
Article
Dropped head syndrome: a rare adverse drug reaction identified in the FDA adverse event reporting system and review of case reports in the literature
Xin Liu, Xiaoyue Zhao, Yangyang He, Yan Tang, Xue-Lian Yan, Bin Zhao & Yi Dai
Pages: 1329-1336
Published online: 22 Mar 2022
AbstractforDropped head syndrome: a rare adverse drug reaction identified in the FDA adverse event reporting system and review of case reports in the literature | Full Text | References | PDF (256.8 KB) | EPUB
  • 435 Views
  • 2 CrossRef citations
  • 0Altmetric

Explore articles